Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. (May 2018)

• Record Type: Journal Article
• Authors: Ballon, Jacob S; Pajvani, Utpal B; Mayer, Laurel ES; Freyberg, Zachary; Freyberg, Robin; Contreras, Ignacio; Rosenbaum, Michael; Leibel, Rudolph L; Lieberman, Jeffrey A
• Is Part Of: Journal of psychopharmacology. Volume 32:Number 5(2018)
• Page Start: 533
• Page End: 540
• Publication Date: 2018-05
• Subjects: Antipsychotic drugs -- weight gain -- obesity -- glucose homeostasis -- randomized clinical trial; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881118754708
• Languages: English
• ISSNs: 0269-8811

Abstract

Second generation antipsychotics are prescribed for an increasing number of psychiatric conditions, despite variable associations with weight gain, dyslipidemia, and impaired glucose tolerance. The mechanism(s) of the apparent causal relationships between these medications and metabolic effects have been inadequately defined and are potentially confounded by genetic risk of mental illness, attendant lifestyle, and concomitant medications. Therefore, we conducted a study in which 24 healthy volunteers were randomized to olanzapine (highly weight-gain liability), iloperidone (less weight-gain liability), or placebo treatment for 28 days under double-blind conditions. We hypothesized that antipsychotics induce weight gain primarily through increased caloric intake, which causes secondary dyslipidemia and insulin resistance. Subjects were phenotyped pre- and post-treatment for body weight, adiposity by dual energy X-ray absorptiometry, energy expenditure by indirect calorimetry, food intake, oral glucose tolerance, plasma lipids, glucose, insulin, and other hormones. We found significantly increased food intake and body weight but no change in energy expenditure in olanzapine-treated subjects, with associated trends towards lipid abnormalities and insulin resistance the extent of which were presumably limited by the duration of treatment. Iloperidone treatment led to modest non-significant and placebo no weightgain, lipid increases and alterations in insulin metabolism. We conclude that second generation antipsychotic drugs, as represented by olanzapine, produce their weight and metabolic effects, predominantly, by increasing food intake which leads to weight gain that in turn induces metabolic consequences, but also through other direct effects on lipid and glucose metabolism independant of food intake and weight gain.